TegoScience Inc (191420) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of TegoScience Inc KRW 3,785, price KRW 7,160, upside -47.1%, quality 34 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.
How to read this chart
60‑month range 5,600 KRW – 29,900 KRW · fair‑value band 2,498 KRW – 4,731 KRW · the 7,160 KRW price screens above the 3,785 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 3, 2026.
Follow TegoScience in your weekly email
Every Wednesday you see whether TegoScience is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
TegoScience Inc. produces and sells wound-healing skin cell therapy products from human epithelial cells in South Korea. The company's products include Holoderm, Kaloderm, and Rosmir. It also provides Neoderm, contract research, and Skinbank services. The company was founded in 2001 and is based in Seoul, South Korea.
Stock analysis
TegoScience Inc (191420) currently trades at 7,160 KRW, while our model-based Fair Value estimate is 3,785 KRW, 47.1% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 94/100, which puts the evidence level at low.
Scenario range: 2,498 KRW (bear) to 4,731 KRW (bull), the price of 7,160 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 34/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
TegoScience Inc reported revenue of 5.9B KRW in FY2025 versus 8.3B KRW in FY2021, a compound −8.0%/yr. Reported net income was −7.0B KRW in FY2025.
Key figures
Market cap 57.3B KRW (≈ $42.7M) · P/S ratio 6.80 · Net margin −118% · Return on equity 705% · Return on assets (EBIT) −2.9% · Operating margin 13.1% · Revenue (TTM) 8.4B KRW · Revenue growth (YoY) +4.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).
What moves the price
The share trades about 61% below its 52-week high and 28% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −40% fair-value upside, at −47%, 191420 screens richer than that median.
Fair Value models
Bear 2,498 KRWFair Value 3,785 KRWBull 4,731 KRW
Price 7,160 KRW · Upside -47.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.24/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−12.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.5%
Start year 2020 (pandemic). Over 10 years: −2.3% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.3%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
17.9% (2020) → −74.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 52 stocks
Beats the industry median on 3/8 measures
Overall it trails its industry peers.
Valuation
Quality Score34 · Bottom 25%
Fair Value upside−47.1% · Below median
Profitability
Return on assets1.4% · Below median
Net margin (TTM)16.0% · Top 25%
Operating margin (TTM)13.1% · Top 25%
Growth and dividend
Revenue growth4.1% · Below median
Balance sheet
Debt / equity0.29× · Highest 25%
Valuation Multiplesvs Pharmaceuticals median · lower = cheaper
EV/EBITDA1.3× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 26
FUTURE (revenue growth)21· sector 51
PAST (return on equity)0· sector 15
HEALTH (low debt)85· sector 98
DIVIDEND (yield)0· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "TegoScience Inc Fair Value". https://www.fairvalue-calculator.com/stock/191420
Frequently asked questions
Is TegoScience Inc (191420) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of 3,785 KRW versus a price of 7,160 KRW, about −47% upside (overvalued).
What is the fair value of 191420?
Our model-based fair value for TegoScience Inc is 3,785 KRW (as of Oct 3, 2026), built from audited fundamentals. The current price: 7,160 KRW.
What is the quality score of 191420?
TegoScience Inc has a Quality Score of 34/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for TegoScience Inc (191420)?
Our model-based price target is the fair value of 3,785 KRW (as of Oct 3, 2026) from 1 valuation models. Cautious scenario 2,498 KRW, optimistic scenario 4,731 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the TegoScience Inc stock forecast for 2026?
Our models put fair value at 3,785 KRW, about −47% upside versus a price of 7,160 KRW (overvalued). Cautious scenario 2,498 KRW, optimistic scenario 4,731 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of TegoScience Inc (191420)?
TegoScience Inc reported trailing-twelve-month revenue of about 8.4B KRW (latest available figure, as of Oct 3, 2026).
What is the intrinsic value of TegoScience Inc (191420)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For TegoScience Inc it is 3,785 KRW per share (as of Oct 3, 2026), against a price of 7,160 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is TegoScience Inc stock overvalued or undervalued in 2026?
As of Oct 3, 2026, 191420 trades above its calculated fair value: price 7,160 KRW, fair value 3,785 KRW, a gap of about −47% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 191420?
No. The price is what the market pays today (7,160 KRW); the fair value is what the company's own numbers justify (3,785 KRW). For TegoScience Inc the two are 3,375 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is TegoScience Inc worth?
The market values TegoScience Inc at about 57.3B KRW (market capitalisation, as of Oct 3, 2026). Per share that is 7,160 KRW; our models calculate a fair value of 3,785 KRW per share.
What do the bullish and bearish scenarios say about 191420?
Our models span a range for TegoScience Inc: cautious scenario 2,498 KRW, base 3,785 KRW, optimistic 4,731 KRW per share (as of Oct 3, 2026, price 7,160 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of TegoScience Inc (191420)?
Balance-sheet figures for TegoScience Inc (as of Oct 3, 2026): debt of 0.29 per unit of equity. They feed the Quality Score of 34/100, which measures business quality independently of the share price.
How far is 191420 from its 52-week high?
TegoScience Inc trades at 7,160 KRW, about 61% below its 52-week high of 18,400 KRW and 28% above the low of 5,600 KRW (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of 3,785 KRW is for.
Which stocks are comparable to TegoScience Inc?
From the same area (Healthcare) we also value Caregen Co, ST Pharm Co, Oscotec Inc, DongKook Pharmaceutical Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is TegoScience Inc stock attractive at the current price?
The data as of Oct 3, 2026: price 7,160 KRW, calculated fair value 3,785 KRW (−47%), Quality Score 34/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 191420 calculated?
We run TegoScience Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 3,785 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.0 % above its aggregate fair value. TegoScience Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of TegoScience Inc (191420)?
The closing price on Oct 2, 2026 was 7,160 KRW. Our model-based fair value is 3,785 KRW, about −47% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with TegoScience Inc right now?
The price sits above even our optimistic bull case (4,731 KRW). The favourable scenario is already priced in. Weak quality (34/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (2,498 KRW to 4,731 KRW) leaves room in how you read the outcome.
Key figures of TegoScience Inc
How large is the market capitalisation of TegoScience Inc (191420)?
The market capitalisation of TegoScience Inc is 57.3B KRW (≈ $42.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of TegoScience Inc (191420)?
The price-to-sales ratio of TegoScience Inc is 6.80 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of TegoScience Inc (191420)?
The net margin of TegoScience Inc is −118% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of TegoScience Inc (191420)?
The return on equity (ROE) of TegoScience Inc is 705% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of TegoScience Inc (191420)?
On an EBIT basis the return on assets of TegoScience Inc is −2.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of TegoScience Inc (191420)?
The operating margin of TegoScience Inc is 13.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at TegoScience Inc (191420)?
Revenue at TegoScience Inc is growing +4.1% versus a year earlier (3y avg −8.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at TegoScience Inc (191420)?
Earnings per share at TegoScience Inc are growing +111% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does TegoScience Inc (191420) generate?
The free cash flow of TegoScience Inc is −3.6B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does TegoScience Inc (191420) carry?
The net debt of TegoScience Inc is 3.4B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch TegoScience Inc in the live analysis
One click puts TegoScience Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
